Mustang Bio, Inc. - MBIO STOCK NEWS

Mustang Bio (MBIO) has received Orphan Drug Designation from the FDA for MB-108, an HSV-1 oncolytic virus targeting malignant glioma. The designation provides tax credits, fee waivers, and seven years of market exclusivity upon approval. The company plans to combine MB-108 with MB-101 (IL13Rα2‐targeted CAR-T cell therapy) in a novel therapeutic approach. Preclinical data shows MB-108 can reshape the tumor microenvironment, potentially enhancing MB-101's efficacy. In previous trials, two patients treated with MB-101 achieved complete responses lasting 7.5 and 31+ months. Further development depends on securing additional funding or strategic partnerships.

Mustang Bio (NASDAQ: MBIO) has entered into a definitive agreement for the exercise of existing warrants to purchase 16,877,638 shares of common stock at $0.237 per share, expected to generate approximately $4 million in gross proceeds. In exchange, the company will issue new unregistered warrants to purchase 33,755,276 shares at $0.27 per share. The new warrants will be exercisable after stockholder approval, with half having a five-year term and half having a twelve-month term. H.C. Wainwright & Co. is acting as the exclusive placement agent. The proceeds will be used for working capital and general corporate purposes.

Mustang Bio (Nasdaq: MBIO), a clinical-stage biopharmaceutical company, has closed a registered direct offering priced at-the-market under Nasdaq rules, raising $2.5 million through the sale of 6,130,000 shares at $0.41 per share. Concurrently, the company issued unregistered warrants for an additional 6,130,000 shares with the same exercise price, expiring five years from stockholder approval. The net proceeds will support working capital and general corporate purposes. H.C. Wainwright & Co. acted as the exclusive placement agent.

Mustang Bio (Nasdaq: MBIO), a clinical-stage biopharmaceutical company, announced a $2.5 million registered direct offering. The company will issue approximately 6.13 million shares at $0.41 per share. Unregistered warrants for the same amount of shares will be issued in a concurrent private placement. The offering is expected to close on June 21, 2024, pending customary conditions. H.C. Wainwright & Co. is the exclusive placement agent. Mustang plans to use the net proceeds for working capital and general corporate purposes.

Mustang Bio has announced positive efficacy and safety data from the Phase 1/2 clinical trial of MB-106, a CD20-targeted autologous CAR-T therapy, for Waldenstrom macroglobulinemia (WM). The trial demonstrated a 90% overall response rate among heavily pretreated patients, with durable responses noted, including one patient in complete remission for 31 months.

Outpatient administration was feasible, and no grade 3 or 4 CRS or severe neurotoxicity was observed. These results were presented at the European Hematology Association 2024 Hybrid Congress. Mustang Bio is developing MB-106 in collaboration with Fred Hutch Cancer Center and aims to advance the program further, contingent on acquiring additional funding or strategic partnerships.

Mustang Bio, Inc. announced the closing of a public offering, generating approximately $4 million in gross proceeds from the sale of common stock and warrants. The Company plans to use the funds for working capital and general corporate purposes. If all warrants are cash-exercised, potential additional gross proceeds of $12 million can be realized. The offering was facilitated by H.C. Wainwright & Co., with the securities offered under a registration statement on Form S-1 filed with the SEC.

Mustang Bio, Inc. announced a public offering of 16,877,638 shares of common stock, along with warrants, at a combined price of $0.237 per share to raise approximately $4 million. The offering is expected to close on May 2, 2024, with H.C. Wainwright & Co. as the placement agent. The proceeds will be used for working capital and general corporate purposes.